[1]CHEN XQ, JIN YY, TANG G.New Materia Medica (17th edition) [M].Beijing:People's Health Publishing House, 2011. (in Chinese) 陈新谦, 金有豫, 汤光.新编药物学 (17版) [M].北京:人民卫生出版社, 2011.
|
[2]TOM H.Oral contraceptives and liver function[J].Clin Patho, 1969, 3:1-10.
|
[3]GARCIA CR, GORDON J, DRILL VA.Contraceptivesteroids and liver lesions[J].J Toxicol Environ Health, 1977, 3 (1-2) :197-206.
|
[4]PEREZ M, SHIELDS CE.Jaundice associatedwith norethindrone acetate therapy[J].New Engl J Med, 1962, 267:1137-1138.
|
[5]PAULA C, BRADY MD, STACEY A, et al.Hepatic adenomas in adolescents and young women with endometriosis treated with norethindrone acetate[J].J Pediatr Adolesc Gynecol, 2017, 30 (3) :422-424.
|
[6]YUAN L, YANG YG, SHEN YX, et al.Research advances in drug-induced liver injury[J].J Clin Hepatol, 2017, 33 (2) :375-378. (in Chinese) 袁玲, 杨永耿, 沈有秀, 等.药物性肝损伤的研究进展[J].临床肝胆病杂志, 2017, 33 (2) :375-378.
|
[7]APARNA S, CARRIE A, ANDREW M, et al.Contraceptive considerations for women withgastrointestinaldisorders[J].Dig Dis Sci, 2017, 62 (1) :54-63.
|
[8]CHU MC, ZHANG X, GENTZSCHEIN E, et al.Formation of ethinyl estradiol in womenduring treatment with norethindrone acetate[J].J Clin Endocrinol Metab, 2007, 92 (6) :2205-2207.
|